Investors Urged to Join Skye Bioscience Securities Fraud Lawsuit

Investors in Skye Bioscience, Inc. (NASDAQ: SKYE) have been alerted to an opportunity to lead a securities fraud lawsuit against the company. The Rosen Law Firm, a global investor rights law firm, is reminding buyers of Skye securities purchased between November 4, 2024, and October 3, 2025, of the upcoming lead plaintiff deadline on January 16, 2026.

Those who acquired securities during this period may be entitled to compensation through a contingency fee arrangement, which means no upfront costs will be incurred. To participate in the class action lawsuit, interested investors can visit the Rosen Law Firm’s dedicated webpage or contact Phillip Kim, Esq. at 866-767-3653 for further information.

The class action has already been initiated, and potential lead plaintiffs must submit their motions to the court by the deadline. A lead plaintiff serves as a representative for other investors in guiding the legal proceedings.

Rosen Law Firm emphasizes the importance of selecting experienced legal representation. Many firms sending out notices may lack the necessary resources or expertise in leading securities class actions. The Rosen Law Firm has established a strong reputation, having secured the largest-ever securities class action settlement against a Chinese company. They have consistently ranked among the top firms for securities class action settlements, recovering hundreds of millions of dollars for investors, including over $438 million in 2019 alone.

The lawsuit alleges that throughout the class period, Skye’s management made materially false and misleading statements regarding the company’s business operations and prospects. Specifically, it is claimed that they misrepresented the effectiveness of the drug nimacimab, overstating its clinical and commercial viability, which subsequently misled investors.

Once the true circumstances surrounding Skye’s operations became public, investors reportedly incurred significant losses. Those wishing to join the class action can still do so by visiting the Rosen Law Firm’s site or contacting them directly.

It is important to note that no class has been certified at this point, meaning investors are not automatically represented unless they retain counsel. Investors also have the option to remain absent from the class and take no action. However, participation as a lead plaintiff does not impact the ability to share in any future recovery.

For updates, investors can follow the Rosen Law Firm on LinkedIn, Twitter, or Facebook. This announcement is provided for informational purposes and does not guarantee any specific outcomes.

For further inquiries, interested parties can reach out to Laurence Rosen, Esq. or Phillip Kim at the firm’s New York office.